Advertisement

American College of Allergy, Asthma, and Immunology

Web Style Guide

Color Palette

#000000;

#000000;

#000000;

#000000;

#000000;

#000000;

#000000;

Typography

h1

This is an h1.

0

h2

This is an h2.

0

h3

This is an h3.

0

h4

This is an h4.

0

h5

This is an h5.

0

h6

This is an h6.

0

lede

This is lede text. It has more text than most headers do.

0

p

This is paragraph text: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

0

a

This is paragraph text: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

0

quote

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

0

caption

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

0

ul

  • This an unordered list
  • This an unordered list
  • This an unordered list

0

ol

  1. This an ordered list
  2. This an ordered list
  3. This an ordered list

0

2 Column List

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

  • Place one on your practice website and another in your electronic patient newsletter.
  • Use individual tips as social media posts.
  • Consider sending one of them to your local media for placement and to introduce yourself as an expert on the topic of allergies and asthma.
  • Personalize an article with your practice information and send it through the mail as an introduction – and public service – to those in your community who suffer from allergies and asthma.
  • Place one on your practice website and another in your electronic patient newsletter.
  • Use individual tips as social media posts.
  • Consider sending one of them to your local media for placement and to introduce yourself as an expert on the topic of allergies and asthma.
  • Personalize an article with your practice information and send it through the mail as an introduction – and public service – to those in your community who suffer from allergies and asthma.

Accordion - Numbered List

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

Accordion - Unordered List

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

Basic Insider Article

First paragraph or two goes here.

Additional paragraphs go here.

Blockquote

Your practice website has become the face of your practice. It’s important to keep your website content fresh and interesting. Consider monitoring the College’s Facebook and  Twitter posts and YouTube videos, and link to these to help add up-to-date content for your website and social media posts.

— Stanley Fineman, MD, MBA, FACAAI

Blue Callout

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

COVID-19 NewsBrief

In an effort to help offset the extra expenses practices have incurred related to COVID-19, the AMA recently approved new CPT code 99072. 99072 is defined as Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency as defined by law, due to respiratory-transmitted infectious disease. While the code has an effective date of September 8, 2020, the Centers for Medicare and Medicaid Services is not yet covering it, and it is unclear when CMS will provide payment policy guidance. The AMA asked CMS to cover the 99072 code at the RUC approved amount of $6.57. Similarly, little is known about whether private payers intend to cover the code, or for how much. Preliminary reports from some practices indicate some private payers are not currently reimbursing for this code, so check with your payers regarding their policy.

Charts + Graphs

COVID-19 Testing

When asked if they were providing any type of COVID-19 testing in their office, 101 out of 291 respondents, or 35%, said they were. Of those, 80% were doing send-out antibody testing, 13% were doing in-house antibody testing, and 39% were doing COVID diagnostic testing.

Source: ACAAI COVID Member Survey 7/30/20 – 8/16/20. Copyright 2020. Data is protected by ACAAI copyright and is prohibited to be shared or published without ACAAI’s consent.

Staffing Issues

When asked if they have furloughed any staff due to COVID-19, a third of the respondents said yes.

Source: ACAAI COVID Member Survey 7/30/20 – 8/16/20. Copyright 2020. Data is protected by ACAAI copyright and is prohibited to be shared or published without ACAAI’s consent.

Federal Response Updates

  • The American Medical Association (AMA), in coordination with the Centers for Medicare and Medicaid Services (CMS), announced new CPT codes for COVID-19 immunization.
  • The Department of Health and Human Services (HHS) announced new partnerships with large chain pharmacies and networks that represent independent pharmacies and regional chains to provide COVID-19 vaccines. This program covers approximately 60 percent of pharmacies throughout the 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands.
  • Both Pfizer and Moderna are expected to submit data to the FDA for an Emergency Use Authorization (EUA) for their respective vaccine candidates in the next few weeks. States are beginning to prepare to distribute vaccines almost immediately upon the FDA issuing an EUA. Johnson & Johnson (J&J) started a new trial for a two-dose regimen of its COVID-19 vaccine candidate. J&J is already conducting a single-dose trial.
  • A new study suggests that rapid COVID-19 tests are less accurate than previously thought.

Congress

On November 17, the Senate Commerce, Science and Transportation Committee holds a hearing on how the COVID-19 pandemic has impacted American manufacturing.

On November 19, the Senate Homeland Security and Government Affairs Committee will hold a hearing on the importance of early outpatient treatment to prevent severe COVID-19 symptoms.

White House and Federal Agencies

The American Medical Association (AMA), in coordination with the Centers for Medicare and Medicaid Services (CMS), announced new CPT codes for COVID-19 immunization.

  • All of the new vaccine-specific CPT codes will be available for use and effective as each new coronavirus vaccine receives Emergency Use Authorization (EUA) or approval from the Food and Drug Administration (FDA).
  • In addition to the long descriptors, short and medium descriptors for the new vaccine-specific CPT codes can be accessed on the AMA website.

The Department of Health and Human Services (HHS) announced new partnerships with large chain pharmacies and networks that represent independent pharmacies and regional chains to provide COVID-19 vaccines. This program covers approximately 60 percent of pharmacies throughout the 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands.

NIAID Director Dr. Anthony Fauci is urging Americans to “double down” on COVID-19 safety measures during this new surge in cases.

The Assistant Secretary for Preparedness and Response (ASPR) has released guidance and best practices for setting up alternate care sites. Alternate care sites (ACS) can help to alleviate health system stress caused by COVID-19 patient surge events. The following resources and documents are intended to support state, tribal, local, and territorial (STLT) governments in the establishment and operation of ACS.

Centers for Disease Control and Prevention (CDC) Updates

This holiday season, consider how your holiday plans can be modified to reduce the spread of COVID-19 to keep your friends, families, and communities healthy and safe. CDC includes information on celebrating Thanksgiving in a safer manner due to the COVID-19 pandemic. NIH Director Dr. Francis Collins also released a blog post with some ideas on how to find other ways besides family gatherings to make the holidays meaningful in Planning Your Holidays During the COVID-19 Pandemic.

According to the CDC, emergency mental health-related visits for children aged 5–11 and 12–17 years have been 24% and 31% higher this year, respectively, compared to April through October of 2019. This suggests COVID-19 is having a mental health impact on children.

In a CDC Scientific Brief examining community use of cloth masks, the authors found that experimental and epidemiological data support community masking to reduce the spread of SARS-CoV-2. The preventive benefit of masking is derived from the combination of source control and personal protection for the mask wearer.

The FDA hosted a virtual FDA Grand Rounds: Facial Coverings During the COVID-19 Pandemic: How well do they flatten the curve? This presentation provides an overview of the FDA’s research to evaluate the ability of facial coverings to reduce the spread of infection and how the FDA is developing a comprehensive risk-assessment tool to predict the probability of infection with individuals wearing a non-surgical face mask or cloth face covering; given the characteristics of non-surgical face masks, the population, and the pathogen. This presentation discusses how the filtration and leakage performance of cloth face coverings, using both experimental and computational methods, input into a risk assessment model the FDA recently developed and is currently calibrating for COVID-19.

CDC has implemented multi-year studies to learn more about the short- and long-term health effects associated with COVID-19. CDC continues to work to identify how common these symptoms are, who is most likely to get them, and whether these symptoms eventually resolve.

CDC updated information on the late sequelae of COVID-19. In peer-reviewed literature and public discussion, persistent symptoms are being reported among COVID-19 survivors, including individuals who initially experience a mild acute illness. These persistent symptoms pose new challenges to patients, healthcare providers, and public health practitioners. CDC also updated a list of the common long-term effects of COVID-19.

Economy, Vaccines, Testing and Treatment

Moderna reported incredibly strong preliminary data on its COVID-19 vaccine candidate that shows it is 94.5 percent effective in preventing illness. National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony Fauci spoke very highly of these preliminary results.

  • Both Pfizer and Moderna are expected to submit data to the FDA for an Emergency Use Authorization (EUA) for their respective vaccine candidates in the next few weeks. States are beginning to prepare to distribute vaccines almost immediately upon the FDA issuing an EUA.

This Op Ed (opposite the editorial page) authored by Dr. Mary I. O’Connor highlights how we can learn from the flu vaccine to improve trust in the COVID-19 vaccine among minority communities.

Johnson & Johnson (J&J) started a new trial for a two-dose regimen of its COVID-19 vaccine candidate. J&J is already conducting a single-dose trial.

A new study suggests that rapid COVID-19 tests are less accurate than previously thought.

COVID-19 treatments for people with early infection are needed urgently, according to a JAMA Viewpoint article by NIAID Director Anthony S. Fauci, M.D., and colleagues. Treating people early in the course of infection with SARS-CoV-2, the virus that causes COVID-19, would speed their recovery, reduce the likelihood they develop severe outcomes and reduce demand on the healthcare system, they write.

COVID-19 test results could be delayed as labs across the country are reaching capacity to deal with the new surge in cases.

New research provides greater insight into why some patients develop more severe COVID-19 symptoms than others.

A new meta-analysis of 50 studies of patients in the U.S. and the U.K. shows how Blacks and Asians have increased COVID-19 infection risk.

Tables

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

If you plan on offering FDA-approved OIT, how has the pandemic affected your implementation timeline?
(218 responses)
# Responses%
No effect on our implementation136.0%
Delayed by 0-3 months209.2%
Delayed by 3-6 months3214.7%
Indefinite delay in implementation8539.0%
I don’t plan on offering FDA-approved OIT6831.2%
Source: ACAAI COVID Member Survey 7/30/20 – 8/16/20. Copyright 2020. Data is protected by ACAAI copyright and is prohibited to be shared or published without ACAAI’s consent.

Toolkit Accordion

Omalizumab, mepolizumab, or reslizumab? This downloadable Put It In Practice resource is designed to make sense of the options for your asthma patients.

Toolkit Blue Callout

Quick tip: Give the biologics cheat sheet to all your front desk and clinical staff. Providers will find it useful, too! But first, customize it to include info specific to your practice.

Toolkit Numbered Accordion

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

This is a text block. Click the edit button to change this text.

Header #1

Insert WYSIWYG here. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Non odio euismod lacinia at quis risus sed. Mauris augue neque gravida in fermentum et sollicitudin. Nam aliquam sem et tortor consequat id.

Header #2

Insert WYSIWYG here. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Non odio euismod lacinia at quis risus sed. Mauris augue neque gravida in fermentum et sollicitudin. Nam aliquam sem et tortor consequat id.

Header #3

Insert WYSIWYG here. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Non odio euismod lacinia at quis risus sed. Mauris augue neque gravida in fermentum et sollicitudin. Nam aliquam sem et tortor consequat id.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam consequat ut ligula sagittis semper. Ut vitae congue sapien. Praesent volutpat maximus urna quis ultricies. Donec at dignissim augue, ut maximus dolor. Vivamus ac vehicula sem. In tincidunt luctus magna, eget condimentum nulla viverra vel. Aliquam ultricies sem ut porta commodo. Donec fringilla ante id magna consectetur, sit amet vulputate velit scelerisque. Duis ac velit enim.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam consequat ut ligula sagittis semper. Ut vitae congue sapien. Praesent volutpat maximus urna quis ultricies. Donec at dignissim augue, ut maximus dolor. Vivamus ac vehicula sem. In tincidunt luctus magna, eget condimentum nulla viverra vel. Aliquam ultricies sem ut porta commodo. Donec fringilla ante id magna consectetur, sit amet vulputate velit scelerisque. Duis ac velit enim.

Lorum Ipsum

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorum Ipsum

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

About the Hosts

Stanley Fineman, MD, MBA, FACAAI

is in private practice at Atlanta Allergy & Asthma as well as being an adjunct associate professor of pediatrics in the allergy section at Emory University School of Medicine. He is editor-in-chief of AllergyWatch and current chair of the College’s Practice Management Committee as well as a past president of the College, and he has received the Distinguished Fellow award.

Merin Kuruvilla, MDThis is the heading

is an assistant professor at Emory University School of Medicine. She is board-certified in allergy/immunology and completed a fellowship at UT Southwestern in Dallas, TX.

Gerald Lee, MD

is an assistant professor of pediatrics and internal medicine in the allergy and immunology section at Emory University School of Medicine. He is the chair of the College's Accreditation and Certification Committee and an assistant editor for AllergyWatch.

Header #1

Insert WYSIWYG here. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Non odio euismod lacinia at quis risus sed. Mauris augue neque gravida in fermentum et sollicitudin. Nam aliquam sem et tortor consequat id.

Header #2

Insert WYSIWYG here. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Non odio euismod lacinia at quis risus sed. Mauris augue neque gravida in fermentum et sollicitudin. Nam aliquam sem et tortor consequat id.

Header #3

Insert WYSIWYG here. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Non odio euismod lacinia at quis risus sed. Mauris augue neque gravida in fermentum et sollicitudin. Nam aliquam sem et tortor consequat id.

Collections Toolkit Copy 3

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

Practice Profitability Toolkit Copy

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. Nibh sit amet commodo nulla facilisi. Adipiscing commodo elit at imperdiet.

Human Resources Toolkit Copy

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. 

Human Resources Toolkit Copy

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. 

Human Resources Toolkit Copy

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. In tellus integer feugiat scelerisque varius morbi enim nunc faucibus. 

Our History

Look back at our past leaders and more than seven decades of work to improve patient care in allergy and immunology.

The Foundation

From helping the public find local allergists to publicizing nationwide asthma screenings, see how the College’s strategic initiatives connect patients — and physicians — to success.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam consequat ut ligula sagittis semper. Ut vitae congue sapien. Praesent volutpat maximus urna quis ultricies. Donec at dignissim augue, ut maximus dolor. Vivamus ac vehicula sem. In tincidunt luctus magna, eget condimentum nulla viverra vel. Aliquam ultricies sem ut porta commodo. Donec fringilla ante id magna consectetur, sit amet vulputate velit scelerisque. Duis ac velit enim.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam consequat ut ligula sagittis semper. Ut vitae congue sapien. Praesent volutpat maximus urna quis ultricies. Donec at dignissim augue, ut maximus dolor. Vivamus ac vehicula sem. In tincidunt luctus magna, eget condimentum nulla viverra vel. Aliquam ultricies sem ut porta commodo. Donec fringilla ante id magna consectetur, sit amet vulputate velit scelerisque. Duis ac velit enim.

Skinny Networks

Overview

Skinny managed care networks – also known as limited or narrow networks – refer to provider networks that restrict their member coverage to just a few select providers. This may also include hospitals and other health care services.

These narrow networks have become more common with the expansion of exchanges under the Affordable Care Act, and often they seem to be directed at providers who treat chronic diseases such as allergies or asthma. (For an in-depth look at skinny networks, see our Advocacy Insider article The ‘Skinny’ on Narrow Networks.)

Our Stance

More skinny networks means that more patients may learn they can no longer see their preferred provider. The Advocacy Council stands against any restrictions to specialty care.

What We’re Doing

The Advocacy Council continues to voice our concerns about these skinny networks to Congress. We recommended:

  • The Centers for Medicare and Medicaid (CMS) should require Qualified Health Plans (QHP) to meet Medicare Advantage Network Adequacy standards.
  • The Essential Community Provider standard of 30% should be maintained.
  • If a QHP drops a provider from its network after the open enrollment period closes, all the provider’s patients in the plan should be notified (in writing) of the change and be allowed 30 days from the date of notification to select a new plan or remain in their original plan.
  • Transparency about which physicians are in-network should be increased.

But we need your help as well!

Take Action

We also suggest you contact both your state and federal legislative officials to express your concerns for your patients.

News

Advocacy Insider is the place to look for all updates on the skinny network issue.

MIPS

Overview

The Merit-based Incentive Payment System (MIPS) was enacted as one of two distinct new payment pathways following the signing of the Medicare Access and CHIP Reauthorization Act (MACRA) in April 2015. Alternative Payment Models, or APMs, represent the other new pathway.

MIPS, which went into effect on Jan. 1, 2017, assigns a composite performance score (0-100) to participating doctors. The score is based on four weighted categories – quality, cost, advancing care information and improvement activities – to determine their payment adjustments. For an in-depth look at this system, including tips for 2017 reporting, explore our MIPS toolkit.

Our Stance

The College has voiced several concerns about MIPS, but we see positives as well. The system is less onerous than the previous one. For example, in 2017 there are six quality measures instead of nine, and an estimated one-third of all allergists are exempt from the program. Also, there are multiple options for practices to participate, and minimal reporting is required to avoid payment penalties. However, there are still few, if any, approved quality measures that relate specifically to allergy specialty care, and reporting is still burdensome for allergy practices.

We are also encouraged by CMS’ proposed changes to MIPS that would become effective in 2018, many of which the College recommended.

What We’re Doing

The Advocacy Council has continually shared its concerns with CMS during the rule-making process, and we are gratified that many of our recommendations have been adopted. Our comments included the following recommendations – all of which were reflected in the new proposed rule for 2018:

  • We launched an aggressive push to raise the low-volume exclusion to $100,000. CMS’ proposed rule raises the limit from $30,000 to $90,000.
  • We recommended postponing the cost measure for at least another year.
  • We recommended allowing physicians to use either the 2014 or 2015 edition of Certified EHR Technology (CEHRT).

Because 2017 is a transition year for MIPS, the Council is continuing to examine the issue and advise practices on who must participate, how best to report and how to maximize their scores. The Advocacy Council is continuing to monitor and comment on proposed changes to MIPS to ensure allergists’ concerns are represented.

Become an Advocate

The Advocacy Council promotes the voice of the allergist, resisting obstacles to our specialty and fighting to protect our future. We need you to take action, too!

News

Stay up to date on MIPS with Advocacy Insider.

APMs

Overview

The Alternative Payment Model (APM) is the second of two new payment vehicles introduced in the 2015 Medicare Access and CHIP Reauthorization Act (MACRA). APMs reward value and quality of care, but also require physicians to carry some financial risk. Beginning in 2019, qualifying Advanced APM participants will earn incentive payments of 5% for six years and will be exempt from payment adjustments under MIPS. To qualify, physicians must participate in an Advanced APM that meets the following criteria:

  • Requires use of electronic health records (EHRs).
  • Reports on quality measures comparable to MIPS quality measures.
  • Places some financial risk on doctors.

There are currently few opportunities for allergists to participate in APMs. But we believe well-designed allergy-specific APMs could be a better financial option for many allergists to provide the best care for patients.

What We’re Doing

The rule encourages specialties to develop APMs that address specific health problems they can control. The Advocacy Council, in turn, has focused on developing the Patient-centered Asthma Care Payment APM.

In March, we submitted our Letter of Intent for this APM to the Physician-focused Payment Model Technical Advisory Committee, which makes recommendations to the U.S. Department of Health and Human Services. Our next step will be to pilot the model in select practices.

News

Stay up to date on APMs with Advocacy Insider.

John Doe

WordPress Developer
Enter member description here which describes the position of member in company

John Doe

WordPress Developer
Enter member description here which describes the position of member in company

John Doe

WordPress Developer
Enter member description here which describes the position of member in company

John Doe

WordPress Developer
Enter member description here which describes the position of member in company

Text Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam consequat ut ligula sagittis semper. Ut vitae congue sapien. Praesent volutpat maximus urna quis ultricies. Donec at dignissim augue, ut maximus dolor. Vivamus ac vehicula sem. In tincidunt luctus magna, eget condimentum nulla viverra vel. Aliquam ultricies sem ut porta commodo. Donec fringilla ante id magna consectetur, sit amet vulputate velit scelerisque. Duis ac velit enim.

 

Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus at velit porta, molestie tortor accumsan, dapibus quam. Vestibulum eu elementum sem, a feugiat neque. Cras ornare neque laoreet neque tempus, sed sodales odio lobortis. Ut quis ornare elit. eget dapibus. Duis vulputate pellentesque sapien, nec venenatis elit dignissim sed. Praesent ornare congue ultricies.

Long Feature Section Headline Section Headline

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.

Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem.

Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

Long Feature Section Headline Section Headline

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.

Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem.

Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

Partners

In Partnership With
Supported By

ACAAI and the Advocacy Council of the ACAAI (the AC) caution that the information provided on this site does not constitute legal advice. In addition, the ACAAI and the AC hereby disclaim any and all liability to any person or entity for any claim, liability, damage or loss resulting from use of or reliance on the information provided herein. In addition, while the information provided is current as of the date of issuance, the ACAAI and the AC assume no obligation to update the information on this site in response to new developments.

Advertisement